

# Venetoclax

**Catalog No: tcsc1155**



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg

**Size:** 1g



## Specifications

**CAS No:**

1257044-40-8

**Formula:**

$C_{45}H_{50}ClN_7O_7S$

**Pathway:**

Apoptosis

**Target:**

Bcl-2 Family

**Purity / Grade:**

>98%

**Solubility:**

H<sub>2</sub>O :

**Alternative Names:**

GDC-0199;ABT-199

**Observed Molecular Weight:**

868.44


**Product Description**

Venetoclax (GDC-0199; ABT-199) is a highly potent, selective and orally bioavailable **Bcl-2** inhibitor with a **K<sub>i</sub>** of less than 0.01 nM.

IC50 & Target: Ki: 444 nM (Mcl-1)<sup>[1]</sup>

**In Vitro:** Venetoclax (ABT-199) potently kills FL5.12-BCL-2 cells (EC<sub>50</sub>=4 nM), Venetoclax (ABT-199) shows much weaker activity against FL5.12-BCL-XL cells (EC<sub>50</sub>=261 nM). ABT-199 also shows selectivity in cellular mammalian two-hybrid assays, where it disrupts BCL-2-BIM complexes (EC<sub>50</sub>=3 nM) but is much less effective against BCL-XL-BCL-XS (EC<sub>50</sub>=2.2 μM) or MCL-1-NOXA complexes<sup>[1]</sup>.

**In Vivo:** After a single oral dose of 12.5 mg per kg body weight in xenografts derived from RS4;11 cells (ALL), Venetoclax (ABT-199) causes a maximal tumor growth inhibition (TGI<sub>max</sub>) of 47% (P[1]. Treatment of established xenografted (a mouse xenograft model of the T-ALL cell line LOUCY) tumors with Venetoclax (ABT-199) 100 mg/kg for 4 days resulted in a significant reduction of leukemic burden (P=0.0048)<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!